RetailWeek: Alliance Boots aims to expand Alphega Pharmacy banner to 10,000 locations
LONDON — Alliance Boots is expanding its network of independent pharmacists operating under the Alphega Pharmacy banner, according to a report published by RetailWeek Friday.
There are already 1,000 Alphega Pharmacy locations in the United Kingdom, according to the report. The pharmacy operation is better known throughout Europe, however, where there are 5,000 franchise members.
Alliance Boots hopes to expand that network of 6,000 pharmacies out to 10,000, RetailWeek reported.
Alphega launched in France in 2001 and broke ground on British soil in 2008. Alphega Pharmacy also can be found in Germany, Italy and Spain, the Netherlands; and in Russia and the Czech republic.
PharmaSmart, Sav-Mor/Sav-On enter kiosk-supply deal
ROCHESTER, N.Y. — PharmaSmart International has signed a deal with Sav-Mor/Sav-On Pharmacies to supply its kiosks in the Michigan-based retail pharmacy network’s stores, PharmaSmart said Friday.
PharmaSmart will install its blood pressure and pulse kiosks in the stores, and patients will be able to access their Blood Pressure Tracker personal health records at Sav-Mor’s and Sav-On’s websites.
"I grew up in the great state of Michigan, and that is where my father practiced medicine for more than 15 years," PharmaSmart COO Ashton Maaraba said. "It means a lot to me to see a homegrown franchise group like Sav-Mor/Sav-On launch the PharmaSmart program and commit to raise hypertension awareness and help drive better outcomes in the communities they serve. We are thrilled to have Sav-Mor/Sav-On as one of our newest global partners."
Pharmacists at the stores and local physicians will be able to better manage patients with high blood pressure and related health conditions, and patients and their providers will be able to use the PharmaSmart personal health record to access the Department of Health and Human Services’ Million Hearts risk-assessment platform, part of a program aimed at preventing 1 million heart attacks by 2017. Sav-Mor/Sav-On plans to use the system for its new Blood Pressure Club, which will be the foundation of the network’s wellness programs.
"The PharmaSmart blood pressure program is exactly what we were looking to implement throughout our stores," Sav-Mor Drug Stores EVP Yvonne Gallagher said. "It is a pure clinical solution in tune with today’s healthcare strategy and patient standard. High blood pressure impacts one of three American adults, and 33 million cases are reported ‘uncontrolled.’"
Reports: ESI may start ‘price war’ over new hepatitis C drugs
NEW YORK — Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.
Bloomberg News reported that ESI would pit companies like Gilead Sciences against others such as AbbVie when the new treatments become available in 2014 or 2015. The Food and Drug Administration announced last week the approval of Gilead’s new drug, Sovaldi (sofosbuvir), which is designed to cut by three quarters the time needed for treatment.
Still, the drugs also are incredibly expensive, with the full 12- to 24-week course of Sovaldi costing $84,000, a cost that ESI chief medical officer Steven Miller told Bloomberg would strain the healthcare system, saying the PBM would "make some really tough formulary decisions." This would mean dropping Sovaldi from its formulary if Gilead’s competitors are willing to sell their drugs for less.
In a post Friday on his Drug Channels blog in response to the Bloomberg story, Pembroke Consulting president Adam Fein wrote that "Put another way, Express Scripts does not view more convenient dosing or administration as justification for higher pricing." Drugs from the new generation of hepatitis C treatments like Sovaldi, Johnson & Johnson’s Olysio (simeprevir) and AbbVie’s experimental three direct-acting-antiviral regimen may be superior to existing treatments — which often require patients to take several medications, including for the depression that’s a common side effect of interferon drugs — but they’re simply too expensive for payers, in other words. In a post in October, Fein noted that interchangeability with cheaper products, rapid price increases, a willingness by payers to trade off choice for cost savings and the presence of co-pay cards explained by Express Scripts excluded 48 drugs from its 2014 formulary.